Global Reach Health – Page 38 – Global Reach Health

January 31, 2022

Savings Opportunities with Upcoming Specialty and Traditional Generics

January, 2023 - The 2022 U.S. Generic and Biosimilar Medicines Savings Report, published by the Association for Accessible Medicines, found that the U.S.

January 21, 2022

Brand Medications with Generic Alternatives Anticipated to
be Approved in February

January 21, 2022 – Selzentry (maraviroc) tablets – for HIV. Adverse reactions or quality problems

January 21, 2022

Veklury Use Expanded in High-Risk COVID-19 Patients

January 21, 2022 – The U.S. FDA has expanded approval and emergency use authorization (EUA) for Gilead's Veklury^® (remdesivir) to treat COVID-19 in certain high-risk individuals

January 19, 2022

One Batch of Semglee Recalled Due to Missing Label

January 19, 2022 – Mylan Pharmaceuticals, a Viatris company, has recalled one batch of non-interchangeable Semglee^® (insulin glargine injection), 100 units/mL (U-100) 3mL

January 14, 2022

Rinvoq Receives New Atopic Dermatitis Indication

January 14, 2022 – AbbVie's Rinvoq^® (upadacitinib) has been approved to treat moderate to severe atopic dermatitis (AD) in patients at least 12 years old who have refractory disease

January 14, 2022

Cibinqo Approved to Treat Atopic Dermatitis

January 14, 2022 – The U.S. FDA has approved Cibinqo^® (abrocitinib) to treat moderate to severe atopic dermatitis in adults who have refractory disease not adequately controlled with other

January 13, 2022

Ryaltris Nasal Spray Approved for Allergic Rhinitis

January 13, 2022 – Ryaltris^TM (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray has been FDA approved to treat the symptoms of seasonal allergic rhinitis in patients

January 12, 2022

New Dental Health Warning for Some Buprenorphine Products

January 12, 2022 – In a drug safety communication, the U.S. FDA has cautioned that dental problems can occur with buprenorphine products that are taken by dissolving them in the mouth